SE9501285L - Förfarande för framställning av biologiskt aktiva proteiner - Google Patents

Förfarande för framställning av biologiskt aktiva proteiner

Info

Publication number
SE9501285L
SE9501285L SE9501285A SE9501285A SE9501285L SE 9501285 L SE9501285 L SE 9501285L SE 9501285 A SE9501285 A SE 9501285A SE 9501285 A SE9501285 A SE 9501285A SE 9501285 L SE9501285 L SE 9501285L
Authority
SE
Sweden
Prior art keywords
biologically active
active proteins
producing biologically
producing
proteins
Prior art date
Application number
SE9501285A
Other languages
English (en)
Other versions
SE9501285D0 (sv
Inventor
Johanna Ljung
Arne Holmgren
Fredrik Aaslund
Original Assignee
Johanna Ljung
Arne Holmgren
Fredrik Aaslund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johanna Ljung, Arne Holmgren, Fredrik Aaslund filed Critical Johanna Ljung
Priority to SE9501285A priority Critical patent/SE9501285L/sv
Publication of SE9501285D0 publication Critical patent/SE9501285D0/sv
Publication of SE9501285L publication Critical patent/SE9501285L/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
SE9501285A 1995-04-06 1995-04-06 Förfarande för framställning av biologiskt aktiva proteiner SE9501285L (sv)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SE9501285A SE9501285L (sv) 1995-04-06 1995-04-06 Förfarande för framställning av biologiskt aktiva proteiner

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9501285A SE9501285L (sv) 1995-04-06 1995-04-06 Förfarande för framställning av biologiskt aktiva proteiner

Publications (2)

Publication Number Publication Date
SE9501285D0 SE9501285D0 (sv) 1995-04-06
SE9501285L true SE9501285L (sv) 1996-10-07

Family

ID=20397877

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9501285A SE9501285L (sv) 1995-04-06 1995-04-06 Förfarande för framställning av biologiskt aktiva proteiner

Country Status (1)

Country Link
SE (1) SE9501285L (sv)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716240B2 (en) 2001-10-10 2014-05-06 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8791066B2 (en) 2004-07-13 2014-07-29 Novo Nordisk A/S Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
US8841439B2 (en) 2005-11-03 2014-09-23 Novo Nordisk A/S Nucleotide sugar purification using membranes
US8853161B2 (en) 2003-04-09 2014-10-07 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US8911967B2 (en) 2005-08-19 2014-12-16 Novo Nordisk A/S One pot desialylation and glycopegylation of therapeutic peptides
US8916360B2 (en) 2003-11-24 2014-12-23 Novo Nordisk A/S Glycopegylated erythropoietin
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US9200049B2 (en) 2004-10-29 2015-12-01 Novo Nordisk A/S Remodeling and glycopegylation of fibroblast growth factor (FGF)
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
JP4951527B2 (ja) 2005-01-10 2012-06-13 バイオジェネリックス アーゲー 糖ｐｅｇ化顆粒球コロニー刺激因子
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8716240B2 (en) 2001-10-10 2014-05-06 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8853161B2 (en) 2003-04-09 2014-10-07 Novo Nordisk A/S Glycopegylation methods and proteins/peptides produced by the methods
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8916360B2 (en) 2003-11-24 2014-12-23 Novo Nordisk A/S Glycopegylated erythropoietin
US8791066B2 (en) 2004-07-13 2014-07-29 Novo Nordisk A/S Branched PEG remodeling and glycosylation of glucagon-like peptide-1 [GLP-1]
US10874714B2 (en) 2004-10-29 2020-12-29 89Bio Ltd. Method of treating fibroblast growth factor 21 (FGF-21) deficiency
US9200049B2 (en) 2004-10-29 2015-12-01 Novo Nordisk A/S Remodeling and glycopegylation of fibroblast growth factor (FGF)
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US8911967B2 (en) 2005-08-19 2014-12-16 Novo Nordisk A/S One pot desialylation and glycopegylation of therapeutic peptides
US8841439B2 (en) 2005-11-03 2014-09-23 Novo Nordisk A/S Nucleotide sugar purification using membranes
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography

Also Published As

Publication number Publication date
SE9501285D0 (sv) 1995-04-06

Similar Documents

Publication Publication Date Title
DE69631903D1 (de) Diskreter gegenstromchromatographieprozess
FI973543A0 (sv) Förfarande för framställning av heteromultimeriska polypeptider
NO982991D0 (no) Veksthormon-sekretagoguer
FI960278A (sv) Förfarande för framställning av anatastitandioxid
DE69620107D1 (de) Kristallisationsverfahren
SE9501285L (sv) Förfarande för framställning av biologiskt aktiva proteiner
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
EP0816510A4 (en) PROCESS FOR PRODUCING BIOLOGICALLY ACTIVE FUSED PROTEINS
FI961378A (sv) Förfarande för framställning av N-metyl-3-(1-metyl-4-piperidinyl)-14-indol-5-etansulfonamid
FI964229A (sv) Förfarande för framställning av doxorubicin
EE03440B1 (et) Bioloogilise toimega bensotiasolooni etaanamiinid ja nende valmistamise protsess
DE69735180D1 (de) Software-Aktualisierungsverfahren
FI973105A0 (sv) Förfarande för framställning av (4,10-diacetoxi-2alfa-bensoyloxi-5beta,20epoxi-1,7beta-dihydroxi-9-oxotax-11-en-13alfa-yl)-(2R,3S)-3-bensoylamino-3-fenyl-2-hydroxipropionaattrihydrat
FI956153A (sv) Förfarande för framställning av vitlut
KR970006251A (ko) 고단백 유기질 비료의 제조방법
ITRM960874A0 (it) Procedimento migliorato per la produzione di 5-idrossimetiltiazolo
FI97725B (sv) Förfarande för framställning av diltiazem
FI973341A (sv) Förfarande för framställning av organosilaner
FI943660A (sv) Framställningsförfarande för 3-karbonylandrostadien-17-karboxamider
FR2768308B1 (fr) Procede de fabrication d'un gel proteique
FI950751A0 (sv) Förfarande för framställning av olefiner
FI97745B (sv) Stödorgan och förfarande för tillverkning av stödorganet
FI951441A0 (sv) Förfarande för framställning av 5-formylamino-pyrimidiner
SE9501550D0 (sv) Förfarande för framställning av transportenhet jämte transportenhet
KR970025786U (ko) 공정용액 분사장치

Legal Events

Date Code Title Description
NAV Patent application has lapsed